Byetta

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
How Big Can This $8 Billion-Plus Diabetes Drug Class Get?
Motley Fool
diabetes
Eli Lilly
Merck
Novo Nordisk
GSK
Byetta
Victoza
Bydureon
Ozempic
Tanzeum
Trulicity
Rybelsus
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
Next stop in AstraZeneca fire sale: China
Next stop in AstraZeneca fire sale: China
BioPharma Dive
AstraZeneca
China
Byetta
Bydureon
Flag link:
Teva seals deal to market copy of AstraZeneca diabetes drug
Teva seals deal to market copy of AstraZeneca diabetes drug
BioPharma Dive
Teva Pharmaceutical
AstraZeneca
Byetta
generics
Flag link:
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States
Teva Settles Patent Litigation with AstraZeneca Allowing Teva to Commercialize Its Generic Version of Byetta® (Exenatide Injection) in the United States
Yahoo
Teva Pharmaceuticals
patents
AstraZeneca
Byetta
Flag link:
AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports
AdverseEvents: Diabetes drug analysis flags heart failure, pancreatitis reports
Fierce Pharma
diabetes
side effects
heart failure
pancreatitis
Nesina
Takeda
Onglyza
AstraZeneca
Farixga
Byetta
Victoza
Januvia
Merck
Novo Nordisk
Flag link:
AstraZeneca Posts Positive Data on its Type II Diabetes Drug
AstraZeneca Posts Positive Data on its Type II Diabetes Drug
Yahoo/Zacks.com
AstraZeneca
diabetes
Byetta
exenatide
Flag link:
FDA eases worries regarding certain diabetes medications
FDA eases worries regarding certain diabetes medications
Yahoo/Fly on the Wall
FDA
diabetes
Merck
Januvia
Janumet
Novo Nordisk
Victoza
Bristol-Myers Squibb
Byetta
Bydureon
Flag link:
Are These Diabetes Drugs Safe After All?
Are These Diabetes Drugs Safe After All?
Motley Fool
Januvia
Merck
Byetta
Bristol-Myers Squibb
diabetes
type 2 diabetes
Flag link:
Diabetes Drugs’ Pancreas Risk Not Backed by Evidence: EMA
Diabetes Drugs’ Pancreas Risk Not Backed by Evidence: EMA
Bloomberg
diabetes
Europe
Byetta
Bristol-Myers Squibb
Merck
Januvia
GLP-1 agonist
Novo Nordisk
Victoza
Flag link:
New GSK diabetes drug works, but faces tough competition
New GSK diabetes drug works, but faces tough competition
Reuters
GSK
diabetes
albiglutide
GLP-1 agonist
Victoza
Byetta
Bydureon
Novo Nordisk
Bristol-Myers Squibb
AstraZeneca
Flag link:
Diabetes Drugs Under Scrutiny As FDA Considers Another Study
Diabetes Drugs Under Scrutiny As FDA Considers Another Study
Pharmalot
FDA
diabetes
Merck
Januvia
Onglyza
Bristol-Myers Squibb
Byetta
AstraZeneca
Eli Lilly
Novo Nordisk
Victoza
Tradjenta
Boehringer Ingelheim
Flag link:
Doctor’s Doubts Imperil Lucrative Diabetes Drugs
Doctor’s Doubts Imperil Lucrative Diabetes Drugs
NY Times, NY
physicians
diabetes
Bristol-Myers Squibb
Byetta
Merck
AstraZeneca
Januvia
Novo Nordisk
Eli Lilly
Takeda
Boehringer Ingelheim
Flag link:
Johnson & Johnson's New Diabetes Drug And Its Competitors
Johnson & Johnson's New Diabetes Drug And Its Competitors
Seeking Alpha
JNJ
diabetes
Invokana
Merck
Januvia
Byetta
Bristol-Myers Squibb
Flag link:
Diabetes Drugs Are Being Evaluated for Pancreatic Risk
Diabetes Drugs Are Being Evaluated for Pancreatic Risk
Bloomberg
pancreatic cancer
diabetes
Merck
Januvia
Bristol-Myers Squibb
Byetta
Novo Nordisk
Victoza
Flag link:
Merck, Bristol Diabetes Drugs Linked to Pancreatitis Risk
Merck, Bristol Diabetes Drugs Linked to Pancreatitis Risk
Bloomberg
Merck
diabetes
Bristol-Myers Squibb
pancreatitis
Januvia
Byetta
Flag link:
FDA: Amylin Pharma Concealed Heart Safety Risks of Key Diabetes Drug
FDA: Amylin Pharma Concealed Heart Safety Risks of Key Diabetes Drug
TheStreet.com
FDA
Amylin
Byetta
diabetes
Flag link:
Novo's Victoza Leads To Greater Weight Loss Than Byetta
Novo's Victoza Leads To Greater Weight Loss Than Byetta
Bloomberg
Byetta
diabetes
Victoza
Novo Nordisk
Amylin
Flag link:
Byetta Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes
Byetta Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl® in Patients with Type 2 Diabetes
Yahoo/Business Wire
Byetta
Amylin
diabetes
type 2 diabetes
Flag link:
Lilly, Amylin receive European approval for expanded use of diabetes treatment Byetta
Lilly, Amylin receive European approval for expanded use of diabetes treatment Byetta
Yahoo/AP
Eli Lilly
Amylin
Europe
diabetes
Byetta
Flag link:

Pages